Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Lithium Americas Corp (LAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Lithium Americas Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.61 (market cap $4.49B), while Lithium Americas Corp trades at $3.52 (market cap $1.27B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 3.5× Lithium Americas Corp's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | LAC | |
|---|---|---|
Market Cap | $4.49B | $1.27B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $10.05 |
52-Week Low | $20.06 | $2.55 |
Enterprise Value | $3.69B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Lithium Americas (LAC) trades at $3.82, up 1.6% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -11.35% and net income of -$122.09M for 2025, though cash flow from financing surged to $1.14B. Construction milestones at Thacker Pass dominate recent news, with analyst consensus leaning toward Hold (53.33%) versus Buy (46.67%) and a $6.25 price target suggesting 64% upside potential.
Outlook remains speculative with high execution risk on Thacker Pass development requiring $1.3-1.6B in 2026 capex. Government support and lithium demand underpin long-term opportunity, but near-term dilution risk from ATM share issuances and negative cash flow from operations (-$61.22M) pressure equity valuation. Investors face binary outcome: project success drives multi-bag returns, while delays or cost overruns could erode shareholder value further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
